A randomized trial of vitamin D supplementation to prevent seasonal influenza and enterovirus infection in children.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as young children.

This randomized, double-blind, controlled trial included children aged two to five years between April 2018 and October 2019 from daycare centers.

The primary outcome was the incidence of influenza and enterovirus infection in the following six months, and the secondary outcome was the incidence of influenza and enterovirus infection in the children's household members.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

The subject headings attached to it are Influenza, Human, Seasons, Dietary Supplements, Vitamin D, Vitamins and Enterovirus Infections.

Author keywords: Influenza infection, Seasonal Influenza and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.